Diagnósticos da América (DASA3) investor relations material

Executive summary

• 2025 marked a strategic transformation with a focus on Diagnostics as the core business, divestment of non-strategic assets totaling R$1.9 billion, and the creation of Rede Américas joint venture, separating hospital operations.

• Operational improvements in productivity, digitalization, AI adoption, and organizational optimization supported margin expansion and efficiency.

• Strengthened financial position through improved cash generation, deleveraging, and disciplined capital allocation.

• Maintained leadership in diagnostics in Latin America, with high patient satisfaction (NPS 76.3 in 4Q25) and ongoing expansion.

• The company operates 840 units, processing over 446 million tests annually across 13 states and the Federal District.

Financial highlights

• Diagnostics revenue grew 13.3% year-over-year in Q4 and 10% for the full year, driven by a 16% increase in exam volume.

• Consolidated gross revenue for 2025 was R$12.2 billion, down 27% year-over-year due to divestments and deconsolidation of hospital operations.

• Recurring EBITDA for 2025 reached R$2.1 billion, up 17% year-over-year, with margin expanding 2.2 p.p. to 21.7%.

• Free cash flow for the year was R$651 million, a 75% increase year-over-year; operating cash generation was R$942 million, up 75.3%.

• Rede Américas reported R$3.4 billion gross revenue in 4Q25, with an adjusted EBITDA margin of 12.2%.

Outlook and guidance

• Entering 2026 with a strong base, the company expects continued growth, profitability, and cash generation, aiming for sustainable value creation.

• Leverage covenant ended 2025 at 2.5x, meeting guidance and remaining below the 4.0x limit.

• Management is optimistic about revenue and margin growth, supported by ongoing efficiency and expansion initiatives.